Vertex Pharmaceuticals (VRTX) EBITDA Margin (2009 - 2026)
Vertex Pharmaceuticals' (VRTX) quarterly EBITDA Margin came in at 38.1% in Q1 2026, up 1536.0% year-on-year from 2.33% in Q1 2025, and up 0.8% quarter-over-quarter from 37.8% in Q4 2025.
Vertex Pharmaceuticals (VRTX) EBITDA Margin (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 38.1% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 1536.0% year-over-year to 38.1% in Q1 2026; TTM through Mar 2026 was 38.31%, a 4500.0% increase from a year earlier, with the FY2025 full-year figure at 34.77%, up 3689.0% from the prior year.
- EBITDA Margin climbed to 38.1% in Q1 2026 per VRTX's latest filing, from 37.8% in the prior quarter.
- Across five years, EBITDA Margin topped out at 50.37% in Q2 2022 and bottomed at 132.85% in Q2 2024.
- The 5-year median for EBITDA Margin is 39.26% (2023), against an average of 29.95%.
- Across the five-year window, EBITDA Margin slumped 17402 bps in 2024 and soared 17168 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 44.88% in 2022, then slipped by 13 bps to 39.26% in 2023, then slipped by 10 bps to 35.23% in 2024, then gained by 7 bps to 37.8% in 2025, then increased by 1 bps to 38.1% in 2026.
- Per Business Quant, the three latest VRTX EBITDA Margin figures stand at 38.1% (Q1 2026), 37.8% (Q4 2025), and 38.56% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.10% |
| Dec 31, 2025 | 37.80% |
| Sep 30, 2025 | 38.56% |
| Jun 30, 2025 | 38.83% |
| Mar 31, 2025 | 22.75% |
| Dec 31, 2024 | 35.23% |
| Sep 30, 2024 | 40.27% |
| Jun 30, 2024 | -132.85% |
| Mar 31, 2024 | 42.35% |
| Dec 31, 2023 | 39.26% |
| Sep 30, 2023 | 41.80% |
| Jun 30, 2023 | 41.17% |
| Mar 31, 2023 | 32.80% |
| Dec 31, 2022 | 44.88% |
| Sep 30, 2022 | 48.27% |
| Jun 30, 2022 | 50.37% |
| Mar 31, 2022 | 49.63% |
| Dec 31, 2021 | 42.35% |
| Sep 30, 2021 | 53.15% |
| Jun 30, 2021 | -2.11% |